Mutations in Keap1 are a potential prognostic factor in resected non‐small cell lung cancer
T Takahashi, M Sonobe, T Menju… - Journal of surgical …, 2010 - Wiley Online Library
T Takahashi, M Sonobe, T Menju, E Nakayama, N Mino, S Iwakiri, S Nagai, K Sato…
Journal of surgical oncology, 2010•Wiley Online LibraryAbstract Background Mutations in Kelch‐like ECH‐associated protein 1 (Keap1) have been
reported to protect tumor cells from chemotherapeutic agents. However, their prognostic
significance in nonsmall cell lung cancer (NSCLC) is still unclear. In this study, we examined
the effect of Keap1 gene mutations on survival and disease‐free interval using resected
primary NSCLC tissue. Methods We retrospectively analyzed the tumors from 79 patients
with completely resected pathological Stage I–II NSCLC for the presence of Keap1 gene …
reported to protect tumor cells from chemotherapeutic agents. However, their prognostic
significance in nonsmall cell lung cancer (NSCLC) is still unclear. In this study, we examined
the effect of Keap1 gene mutations on survival and disease‐free interval using resected
primary NSCLC tissue. Methods We retrospectively analyzed the tumors from 79 patients
with completely resected pathological Stage I–II NSCLC for the presence of Keap1 gene …
Background
Mutations in Kelch‐like ECH‐associated protein 1 (Keap1) have been reported to protect tumor cells from chemotherapeutic agents. However, their prognostic significance in nonsmall cell lung cancer (NSCLC) is still unclear. In this study, we examined the effect of Keap1 gene mutations on survival and disease‐free interval using resected primary NSCLC tissue.
Methods
We retrospectively analyzed the tumors from 79 patients with completely resected pathological Stage I–II NSCLC for the presence of Keap1 gene mutations and examined the prognosis of the patients.
Results
Keap1 gene mutations were detected in four patients (5.1%). The postoperative 5‐year survival rate for patients with Keap1 mutations was significantly lower than those without a mutation (25% vs. 76%, P = 0.038). The postoperative 5‐year disease‐free survival rate for patients with a mutant Keap1 tumor was slightly lower than for patients with Keap1 wild‐type tumors (25% vs. 66%, P = 0.057).
Conclusions
Keap1 gene mutations are likely to be associated with a worse prognosis and lower postoperative disease‐free survival rates in pathological Stage I–II NSCLC. J. Surg. Oncol. 2010; 101:500–506. © 2010 Wiley‐Liss, Inc.
Wiley Online Library